Affymetrix Q3 Revenues Rise 1 Percent on 'Strong Growth' in Genetic Analysis Business | GenomeWeb

NEW YORK (GenomeWeb News) – Affymetrix reported after the close of the market on Wednesday that its third quarter revenues rose 1 percent year over year.

Total revenues for the three months ended Sept. 30 were $80.4 million, compared to $79.6 million in the same period last year. The results beat the average Wall Street estimate of $79 million for the quarter.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Sure Genomics begins to offer direct-to-consumer genome sequencing for $2,500.

Intelligence officials in the US have added gene editing to a list of weapons of mass destruction.

In Cell this week: characterization of functional genomic features in breast cancer cell lines, epigenetic pattern linked to obesity, and more.

President Obama's proposed budget for fiscal year 2017 includes an increase for NIH, but seeks some of it as mandatory funding.